Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Dave Belz who wrote (749)	11/21/1997 11:46:00 AM
From: EZLibra	Respond to of 3702

Dave, most the answers are on the thread somewhere but I'll try to be quick. I have a 4 o'clock appointment 3 1/2 hrs from here. The article was syndicated from a speech Dr. Folkman made at the NIH, which is next door to his Rockville company, EntreMed. It should be obvious to all that a cancer treatment as efficacious as one requiring surgery (which is always radical) and which is obviously less expensive would be the treatment of choice. Every product Techniclone has is designed to obviate the need for surgery and even to be performed on an outpatient basis. The glioma trial Phase I is involving surgery only to prove safety, TNT will be injected into the cavity after tumor removal. Once safety is established the Phase II-III will involve IV and spinal injection. All three delivery methods have proven efficacious in China. You're reading the same release I am, but it seems obvious that Alpha does not have a license to Lym-1 anymore and any accruals will be repatriated in milestone payments. Who will be the new licensee/distributor? That is the million dollar question, or if you believe the professional touts of Idec/Coulter, the half a billion dollar question. Coulter also has not licensed their ab, this could prove very interesting. Just on NHL has anyone compared the market caps of IDPH, CLTR, and TCLN lately? Previously TCLN said that they could not disseminate the clinical data on Lym-1 because they did not own it. Now they do and I expect them to do so.